Study guide
6.3 IRB/IEC Composition and Independent Review
ACRP CCRA Certified Clinical Research Associate Study Guide 2026 Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Exam Format, Eligibility and Registration
1.1 Exam Format, Eligibility and Current References 1.2 Registration, Fees and Candidate Decisions
2 Chapter 2: CRA Responsibilities and Study Planning
2.1 The CRA Role, Data Integrity and Product Oversight 2.2 Official Blueprint and Study Strategy
3 Chapter 3: Protocols, Endpoints and Trial Design
3.1 Protocol Elements and Endpoint Hierarchy 3.2 Endpoint Interpretation and Eligibility Rationale 3.3 Eligibility Verification and Trial Designs
4 Chapter 4: Bias Control, Blinding and Product Information
4.1 Bias, Randomisation and Comparator Controls 4.2 Unblinding and Investigator Brochure Content 4.3 Reference Safety Information and IB Updates
5 Chapter 5: Estimands and Device Instructions
5.1 Estimands and Intercurrent Events 5.2 Device Instructions, Configuration and Training
6 Chapter 6: Ethical Foundations and Independent Oversight
6.1 Ethical Foundations and the 2024 Declaration of Helsinki 6.2 Vulnerability, Voluntariness and Compensation 6.3 IRB/IEC Composition and Independent Review
7 Chapter 7: Ethics Communication and Informed Consent
7.1 Ethics Reporting, Approval Status and Version Control 7.2 Informed Consent Information and Meaningful Choice 7.3 Consent Documentation, Special Circumstances and Updates
8 Chapter 8: Recruitment, Retention and Confidentiality
8.1 Ethical Eligibility, Recruitment and Retention 8.2 Privacy, Confidentiality and Appropriate Access
9 Chapter 9: Safety Definitions and Classification
9.1 Adverse Event Definitions and Actual Life-Threatening Risk 9.2 Seriousness, Severity and Medical Importance 9.3 Causality, Expectedness and Reference Safety Information
10 Chapter 10: Safety Detection, Reporting and Oversight
10.1 Detecting Events, AESIs and Collection Windows 10.2 Expedited Reporting and the Sponsor Awareness Clock 10.3 Immediate Site Reporting and Independent Safety Oversight
11 Chapter 11: Follow-Up, Adherence and Conflicts
11.1 Safety Communications, Reconciliation and Follow-Up 11.2 Adherence, Discontinuation and Participant Choice 11.3 Conflicts of Interest and Prorated Payments
12 Chapter 12: Development Stages and Product Management
12.1 Nonclinical Background and Human Pharmacology 12.2 Exploratory, Confirmatory and Therapeutic-Use Studies 12.3 Product Storage, Labelling and Excursion Response
13 Chapter 13: Accountability, Integrity and Regulatory Status
13.1 Product Accountability and Adherence Calculations 13.2 Potential Fraud, Misconduct and Evidence Preservation 13.3 Submissions, Authorisation Status and Trial Reporting
14 Chapter 14: Current GCP Principles and Delegation
14.1 The Eleven Current GCP Principles 14.2 Proportionality and Investigator Oversight 14.3 Delegation, Qualifications and Task Authority
15 Chapter 15: Oversight, Protocol Control and Amendments
15.1 Clinical Oversight and Immediate-Hazard Changes 15.2 Deviation Classification and Resolution
16 Chapter 16: Implementation and Trial Responsibilities
16.1 Amendment Implementation and Communication 16.2 Sponsor, Investigator and Service-Provider Roles
17 Chapter 17: Quality Planning, Root Causes and CAPA
17.1 Quality Planning and Risk Management 17.2 Root Cause Analysis and CAPA Design 17.3 CAPA Implementation and Effectiveness Verification
18 Chapter 18: Risk Assessment and Monitoring Methods
18.1 Risk Assessment and Centralised Surveillance 18.2 Monitoring Methods and Source Review
19 Chapter 19: Quality Metrics, Plans and Communication
19.1 KRIs, Acceptable Ranges and Trial-Level Quality 19.2 Monitoring Plans, Co-Monitoring and Communication
20 Chapter 20: Site Qualification and Readiness
20.1 Site Qualification and Investigator Capacity 20.2 Recruitment Feasibility and Evidence-Based Site Selection 20.3 Site Readiness and Activity-Specific Release
21 Chapter 21: Initiation, Equipment and Supplies
21.1 Initiation Training and Readiness Walkthroughs 21.2 Equipment, Maintenance and Study Supplies
22 Chapter 22: Samples, Diagnostics and Financial Feasibility
22.1 Specimens, Diagnostic Results and Rater Quality 22.2 Contracts, Budgets and Operational Feasibility
23 Chapter 23: Interim Monitoring and Reporting
23.1 Interim Visit Preparation and Consent Review 23.2 Monitoring Eligibility, Safety and Products 23.3 Investigator Debrief and Monitoring Reports
24 Chapter 24: Essential Records, Audits and Findings
24.1 Essential Records and Site/Sponsor Reconciliation 24.2 Version History, Resolution Evidence and Noncompliance 24.3 Audits, Inspections and Closure Planning
25 Chapter 25: Close-Out, Retention and Destruction
25.1 Close-Out, Archiving and Continuing Obligations 25.2 Retention, Destruction and Long-Term Access
26 Chapter 26: Source Records and Good Documentation
26.1 Source Records and Foundational ALCOA Principles 26.2 Good Documentation, Completeness and Corrections 26.3 Source Access, Certified Copies and Context
27 Chapter 27: Electronic Systems, Metadata and Queries
27.1 EDC Design and Fit-for-Purpose Systems 27.2 Audit Trails, Electronic Outcomes and Device Choice 27.3 Queries, Coding and Supported Clinical Meaning
28 Chapter 28: Dataset Finalisation and Critical Data
28.1 Safety Reconciliation and Dataset Finalisation 28.2 Critical Data, Acquisition Tools and Interim Findings
6.3 IRB/IEC Composition and Independent Review
Key Takeaways Explain This Topic AI
E6(R3) recommends at least five committee members with suitable collective expertise.
Only members independent of the investigator and sponsor should vote or provide an opinion.
Quorum is defined in the committee’s documented procedures and applicable requirements.
Last updated: October 2026
IRB/IEC Composition and Independent Review
Payment Schedule & Accounting Verification: Review site payment logs and financial records against the IRB-approved Informed Consent Form (ICF) and protocol schedule. Verify that payments are prorated according to completed visits and that subjects who withdrew early received their earned prorated amounts.
Vulnerable Population Enrollment Audits: Review source documentation for any enrolled vulnerable subjects. Ensure that pediatric assent forms match the participant's age at enrollment, that LAR documentation satisfies jurisdictional applicable requirements, and that no clinic or university subordinates were enrolled under coercive conditions.
Withdrawal Documentation: Confirm that when a participant chooses to withdraw, the site honors their decision immediately, documents the withdrawal in medical source records without badgering the subject, and offers standard medical follow-up for safety without prejudice.
Institutional Review Boards & Independent Ethics Committees (IRB/IEC)
Note
In the regulatory architecture of clinical research, the Institutional Review Board (IRB) or Independent Ethics Committee (IEC) serves as the primary independent entity responsible for prospective and ongoing human subject protections. Required ethics approval must precede trial participation. Protocol changes follow the applicable review process, with provisions for immediate hazards and permitted purely administrative/logistical changes under applicable requirements.
An Institutional Review Board (IRB) and an Independent Ethics Committee (IEC) share the identical core mandate: safeguarding the rights, safety, and well-being of trial subjects. For the Clinical Research Associate (CRA), verifying that valid, current, and unambiguous ethics committee approvals are maintained throughout the trial lifecycle is one of the most critical monitoring obligations.
Definition and Primary Responsibilities (ICH E6(R3))
Under ICH E6(R3), an IEC is defined as an independent body (a review board or a committee, institutional, regional, national, or supranational), constituted of medical professionals and non-medical members, whose responsibility it is to ensure the protection of the rights, safety, and well-being of human subjects involved in a trial and to provide public assurance of that protection.
According to ICH E6(R3), the IRB/IEC should review the following information as applicable when evaluating the trial:
- The clinical trial protocol and any amendments
- Written informed consent forms and consent form updates
- Subject recruitment procedures and advertisements
- Written information to be provided to subjects (e.g., patient diaries, instruction sheets)
- The Investigator's Brochure (IB) and available safety information
- Information about payments and compensation available to subjects
- The investigator's current curriculum vitae (CV) and other documentation evidencing qualifications
- Any other documents the IRB/IEC may require to fulfill its responsibilities
The committee must pay special attention to reviewing trials that involve vulnerable subjects (such as children, prisoners, pregnant women, or cognitively impaired individuals) to ensure adequate supplemental safeguards are established.
Membership Composition and Governance Rules
To ensure diverse perspectives, balanced ethical judgment, and protection against institutional bias, E6(R3) recommends a multidisciplinary composition and documented procedures:
Independent decisions and documented review procedures
Under E6(R3) Annex 1, membership should collectively cover scientific, medical and ethical expertise. ICH recommends at least five members, including a member outside medical sciences and one independent of the institution/site. Only members independent of the investigator and sponsor should vote or provide an opinion. Investigators and sponsor personnel may answer questions but should not take part in the decision.
The committee's documented procedures specify quorum. Do not substitute a universal national quorum formula for the international guideline. Decisions should identify the trial, documents reviewed, dates and outcome: approval, modifications required before approval, negative opinion, or suspension/termination. A request for modifications is not permission to start while the conditions remain unresolved.
Expedited review of minor changes follows applicable requirements and committee procedures. Country-specific exemption categories and limits on expedited disapproval are not a universal ICH examination rule. Verify the actual review determination rather than accepting an investigator's self-declared exemption.
Central IRB vs. Local / Institutional IRB
Institutional (Local) IRB: Based within a specific university, academic medical center, or hospital. Local IRBs possess deep familiarity with institutional infrastructure, local clinical practice, community values, and state laws.
Central IRB (Single IRB / sIRB): An independent or central review board that provides ethical oversight across multiple trial sites participating in a multi-center study under a formal reliance agreement (IRB authorization agreement). The sIRB model harmonizes review decisions, reduces redundant paperwork across sites, accelerates study activation, and provides centralized safety oversight.
Ongoing Oversight: Protocol Amendments and Continuing Review
IRB oversight does not conclude with initial study approval; it persists throughout the entire duration of the trial:
Official sources
Checked October 18, 2026: ICH E6(R3), Principles and Annex 1 , WMA Declaration of Helsinki, 2024 , ICH E11(R1) .